Skip to content

Investigating the effect of rivastigmine on the cognitive performance of HIV positive people

A randomized clinical trial study on the safety and efficacy of rivastigmine on cognitive function in HIV infected patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130719014054N3
Enrollment
148
Registered
2024-10-02
Start date
2024-08-05
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive disorders in patients with HIV. Mild cognitive impairment, so stated

Interventions

Intervention 1: Intervention group: After obtaining informed consent and signing the informed consent form and explaining how to conduct the study, the patients demographic information such as age and

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Adult HIV patients (age between 18 and 65 years old) with cognitive impairment referring to outpatient clinics at Imam Khomeini Hospital Patients have been under antiretroviral treatment for at least 6 months and have a viral load of less than 200 copies per milliliter of blood.

Exclusion criteria

Exclusion criteria: Efavirenz drug use Having an active infection (such as opportunistic infections) Having symptoms of hepatic and renal encephalopathy Using methamphetamines Taking anticholinergic drugs History of coagulation disorder History of taking anticoagulant and antiplatelet drugs History of allergy to rivastigmine drug History of known arrhythmia (such as 2nd and 3rd degree blocks) or sick sinus syndrome History of urinary tract obstruction Acute gastrointestinal ulcer Concomitant use of cholinesterase inhibitor drugs History of epilepsy Pregnant and breastfeeding people Having suicidal thoughts chronic inflammatory diseases such as RA and IBD

Design outcomes

Primary

MeasureTime frame
The improvement rate of cognitive impairment. Timepoint: At the beginning and end of the study. Method of measurement: based on the score of CANTAB software.

Secondary

MeasureTime frame
Improving the level of depression, stress and anxiety. Timepoint: The beginning and end of the study. Method of measurement: Based on the DASS21 questionnaire.;Improving the CD4+ cell count. Timepoint: The beginning and end of the study. Method of measurement: based on blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLadan Abbasian

Tehran University of Medical Sciences

la.abbasian@gmail.com+98 21 6119 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026